Semaglutide Resolves NASH in 63% of Patients in Phase 3 ESSENCE Trial (NCT04822181)

The ESSENCE trial, a Phase 3 randomized placebo-controlled study registered as NCT04822181, has produced the most compelling histological evidence yet that a GLP-1 receptor agonist can meaningfully reverse non-alcoholic steatohepatitis. Results from a 72-week interim analysis of 800 patients, published April 30, 2025 in the New England Journal of Medicine (PMID: 40305708, DOI: 10.1056/NEJMoa2413258), show that semaglutide 2.4 mg weekly resolved steatohepatitis without worsening liver fibrosis in 62.9% of treated patients, versus 34.3% in the placebo group. The 28.7 percentage-point difference is large by any measure in hepatology.

Both co-primary endpoints were met. Beyond steatohepatitis resolution, fibrosis stage improved in 36.8% of semaglutide patients versus 22.4% of placebo patients, a 14.4 percentage-point difference that carries its own independent significance for long-term liver outcomes. The trial remains active and will assess cirrhosis-free survival through week 240, approximately five years from enrollment.

The disease studied, now formally reclassified as metabolic dysfunction-associated steatohepatitis (MASH), affects an estimated 1.5-6.5% of adults globally. Without effective intervention, a subset progress to cirrhosis, hepatocellular carcinoma, and liver failure. Until recently, no pharmacological agent had demonstrated large-scale efficacy in Phase 3 liver histology trials.

Background: The NASH Treatment Landscape Before ESSENCE

Non-alcoholic steatohepatitis is defined by the coexistence of hepatic steatosis, hepatocyte injury (ballooning), and lobular inflammation, with or without fibrosis. Fibrosis stage (F0-F4 on the METAVIR or Ishak scale) is the strongest predictor of clinical outcomes including cirrhosis and mortality. Achieving fibrosis regression, not just steatohepatitis resolution, is the outcome that changes disease trajectory.

For decades, no drug obtained FDA approval with a primary endpoint of liver histology improvement in NASH. Lifestyle intervention, specifically caloric restriction and aerobic exercise, reliably reduces intrahepatic fat and can reverse early fibrosis, but adherence at the population level is poor. Bariatric surgery produces sustained histological improvement but carries procedural risk and is reserved for a subset of patients.

The pharmacological pipeline generated multiple high-profile failures. Obeticholic acid, a farnesoid X receptor agonist, achieved borderline fibrosis improvement in the REGENERATE trial but failed to meet accelerated approval criteria for clinical outcomes. Selonsertib (an ASK1 inhibitor) failed Phase 3. Elafibranor (a PPAR alpha/delta agonist) failed Phase 3. The pattern established the hepatology community’s warranted skepticism about Phase 2 results translating to Phase 3.

Resmetirom (Rezdiffra), a thyroid hormone receptor-beta agonist, became the first FDA-approved drug for MASH with fibrosis in 2024, achieving approximately 26% fibrosis improvement in the MAESTRO-NASH trial. Its approval was granted under accelerated approval with histological endpoints as surrogate markers for clinical outcomes.

Into this setting, the ESSENCE trial arrived with mechanistic logic: GLP-1 receptor agonists drive weight loss, reduce visceral adiposity, suppress hepatic fat synthesis, and attenuate systemic inflammation, all pathways relevant to MASH pathogenesis.

Trial Design: What NCT04822181 Set Out to Test

The ESSENCE study (official title: “The Effect of Semaglutide in Subjects With Non-cirrhotic Non-alcoholic Steatohepatitis”) is a double-blind, placebo-controlled Phase 3 trial sponsored by Novo Nordisk. It enrolled 1,205 participants at sites globally, beginning April 2021, with an estimated primary completion date of April 2029.

Enrollment criteria specified biopsy-confirmed MASH with fibrosis stages F2 or F3, the fibrosis range where reversal is both achievable and clinically meaningful, before the endpoint of F4 cirrhosis renders the target population too advanced for meaningful histological recovery.

The trial is structured in two parts:

Part 1 (Week 72 interim): Two co-primary endpoints assessed in a prespecified interim population of 800 patients.

• Resolution of steatohepatitis with no worsening of liver fibrosis
• Improvement in liver fibrosis stage by at least one stage with no worsening of steatohepatitis

Part 2 (Week 240 primary): Cirrhosis-free survival, assessed approximately five years post-enrollment in the full 1,205-participant cohort.

The week 72 interim data published in PMID 40305708 represent Part 1. Part 2 remains ongoing; the trial’s active-not-recruiting status as of April 2026 reflects that enrollment is complete and follow-up continues.

Participants received subcutaneous semaglutide 2.4 mg once weekly, the chronic weight management dose used in the STEP trial program, not the 1.0 mg type 2 diabetes dose. Liver biopsies were performed at baseline and at week 72 to assess histological endpoints. Up to 21 clinic visits and 9 telephone contacts over approximately five years comprise the trial schedule.

flowchart TD
    A[1,205 Patients Enrolled\nBiopsy-confirmed MASH F2-F3\nNCT04822181] --> B[Randomization\nDouble-Blind]
    B --> C[Semaglutide 2.4 mg SC\nOnce Weekly]
    B --> D[Placebo\nOnce Weekly]
    C --> E[Week 72 Biopsy\nPart 1 Interim Analysis\nn=800]
    D --> E
    E --> F[Primary Endpoint 1\nSTH Resolution, No Fibrosis Worsening\n62.9% vs 34.3%\np<0.001]
    E --> G[Primary Endpoint 2\nFibrosis Reduction, No STH Worsening\n36.8% vs 22.4%\np<0.001]
    C --> H[Week 240\nPart 2 Primary\nCirrhosis-Free Survival]
    D --> H
    H --> I[Results Pending\nEstimated 2029]

    style C fill:#3b82f6,color:#fff
    style D fill:#6b7280,color:#fff
    style F fill:#10b981,color:#fff
    style G fill:#10b981,color:#fff
    style I fill:#f59e0b,color:#fff

Primary Results at Week 72: Both Endpoints Met by Wide Margins

The 72-week interim analysis drew from 800 of the 1,205 enrolled participants. The data show statistically and clinically significant separation on both co-primary endpoints.

Steatohepatitis resolution without fibrosis worsening:

A 28.7 percentage-point difference in a histological endpoint, confirmed by liver biopsy, is not a marginal finding. For context, a Phase 2 trial of semaglutide 0.4 mg daily in NASH (PMID: 31185131, Newsome et al., NEJM 2021) reported steatohepatitis resolution in 59% of semaglutide-treated patients versus 17% for placebo, signaling strong dose-dependent efficacy that NCT04822181 now confirms at Phase 3 scale with the 2.4 mg dose.

Fibrosis improvement without steatohepatitis worsening:

The fibrosis endpoint carries particular clinical weight. Fibrosis stage is the primary histological correlate of long-term outcomes in MASH, including progression to cirrhosis, portal hypertension, and hepatocellular carcinoma. Achieving a one-stage improvement in F2-F3 patients, without worsening inflammation, alters the expected disease trajectory.

Combined endpoint (both resolved):

Approximately one-third of semaglutide-treated patients simultaneously resolved steatohepatitis and improved fibrosis stage at 72 weeks. This combination is the ideal histological outcome.

Secondary Outcomes: Weight Loss and Biomarkers

Body weight change is a pre-specified secondary endpoint in ESSENCE and a mechanistically central variable.

Body weight change at Week 72:

A 10.5% mean body weight reduction in a population with metabolic liver disease is highly clinically relevant. Weight loss of 7-10% has been associated with histological improvement in NASH in multiple lifestyle intervention studies. The semaglutide group reached and exceeded this threshold on average; the placebo group, at 2.0% loss, largely did not.

The magnitude of weight loss also provides mechanistic context for the liver histology improvements. Hepatic fat content tracks closely with total body weight in MASH patients; weight-driven reductions in intrahepatic triglycerides reduce hepatocellular stress and lipotoxic injury, potentially reversing the inflammatory cascade that produces steatohepatitis.

Secondary endpoints also included changes in ALT, AST, ELF score (Enhanced Liver Fibrosis test), Pro-C3 (a marker of hepatic fibrogenesis), inflammatory markers, lipid profile, and quality of life assessed by SF-36. Full secondary endpoint data are reported in the complete NEJM publication (PMID: 40305708).

Mechanism: How Semaglutide Acts on the MASH-Diseased Liver

Semaglutide is a long-acting GLP-1 receptor agonist with half-life of approximately one week, enabling once-weekly subcutaneous dosing. Its primary approved mechanisms operate in the pancreas (stimulating insulin secretion in a glucose-dependent manner), the hypothalamus (reducing appetite and caloric intake), and the gastrointestinal tract (slowing gastric emptying). In MASH, several of these mechanisms converge on hepatic pathology.

Hepatic fat reduction via weight loss. Caloric restriction and weight loss, whether from lifestyle change or pharmacotherapy, reliably reduce intrahepatic triglycerides. GLP-1 receptor agonists produce substantial and sustained weight loss by suppressing appetite centrally and slowing gastric emptying. The 10.5% body weight reduction in ESSENCE places most treated patients in the range historically associated with histological NASH improvement.

Direct hepatic GLP-1 receptor signaling. GLP-1 receptors are expressed on hepatocytes, though at lower density than in pancreatic beta cells. Pre-clinical data suggest that GLP-1 receptor activation in the liver suppresses de novo lipogenesis via cAMP-PKA signaling and reduces hepatic glucose production. Whether direct hepatic receptor activation contributes meaningfully to the ESSENCE outcomes, independent of weight loss, is difficult to disentangle from current data.

Anti-inflammatory signaling. GLP-1 receptor agonists suppress NF-kB-mediated inflammatory gene expression in macrophages, including Kupffer cells, the resident hepatic macrophages that amplify liver inflammation in MASH. Reduced Kupffer cell activation attenuates production of TNF-alpha, IL-1beta, and IL-6, the cytokines that drive hepatocellular injury and ballooning.

Insulin sensitization. Insulin resistance is central to MASH pathogenesis. Hyperinsulinemia promotes hepatic lipogenesis and impairs fatty acid oxidation. Semaglutide’s weight loss-driven improvement in insulin sensitivity reduces the hepatic lipid burden indirectly through improved peripheral glucose disposal and reduced adipose-derived free fatty acid flux to the liver.

flowchart LR
    A[Semaglutide 2.4 mg SC\nGLP-1 Receptor Agonist] --> B[Hypothalamic Appetite Suppression]
    A --> C[Gastric Emptying Slowing]
    A --> D[Hepatic GLP-1R Signaling\ndirect, modest]
    A --> E[Pancreatic Insulin Release\nglucose-dependent]
    B --> F[Caloric Deficit\nWeight Loss 10.5%]
    C --> F
    F --> G[Reduced Intrahepatic Triglycerides\nSteatosis Reversal]
    D --> H[Reduced NF-kB in Kupffer Cells\nAnti-inflammatory]
    E --> I[Improved Insulin Sensitivity\nReduced Lipogenesis]
    G --> J[Steatohepatitis Resolution\n62.9% vs 34.3%]
    H --> J
    I --> J
    J --> K[Fibrosis Improvement\n36.8% vs 22.4%]

    style A fill:#3b82f6,color:#fff
    style J fill:#10b981,color:#fff
    style K fill:#10b981,color:#fff

Safety: Gastrointestinal Adverse Events Dominate the Profile

Gastrointestinal adverse events were more frequent in the semaglutide group, consistent with the established tolerability profile of GLP-1 receptor agonists across all trials. Nausea, vomiting, diarrhea, and constipation are the most commonly reported effects. These events are typically dose-dependent, most prominent during dose escalation, and tend to attenuate after several weeks of steady-state exposure.

The STEP trial program, which established the 2.4 mg semaglutide dose in obesity, provides the most relevant safety reference database. In STEP-1 (PMID: 33567185), gastrointestinal adverse events led to treatment discontinuation in approximately 4.5% of semaglutide-treated patients versus 0.8% in the placebo group. Serious adverse events were similar between groups.

The ESSENCE abstract (PMID: 40305708) does not report granular safety data. Complete adverse event tabulation, serious adverse event rates, discontinuation rates, and hepatic-specific safety findings are available in the full NEJM publication. No unexpected hepatic safety signals were flagged in the published communications around the trial results.

For a population with pre-existing liver disease, hepatic safety monitoring is particularly relevant. ALT and AST elevations during GLP-1 agonist therapy have been reported in some trials, though generally attributed to transient hepatic adaptation rather than drug-induced liver injury. The ESSENCE protocol includes comprehensive liver biomarker monitoring through all study visits.

Placing ESSENCE in Context: Comparison with Other MASH Drugs

The ESSENCE results outperform previously reported Phase 3 MASH data in steatohepatitis resolution, though direct comparisons across trials carry significant caveats related to population differences, fibrosis stage distribution, and endpoint operationalization.

Resmetirom (MAESTRO-NASH): Fibrosis improvement in approximately 26% of treated patients at 52 weeks (PMID: 38537017). Steatohepatitis resolution in approximately 36%. Resmetirom received FDA approval in 2024 on these data.

Semaglutide 2.4 mg (ESSENCE, PMID: 40305708): Fibrosis improvement in 36.8%, steatohepatitis resolution in 62.9%, at 72 weeks.

Lanifibranor (NATIVE trial): Fibrosis improvement in approximately 49% of patients with high-dose (1,200 mg) treatment at 24 weeks. Steatohepatitis resolution in approximately 49%. Phase 3 confirmatory data are pending.

The ESSENCE results represent the largest steatohepatitis resolution rate reported in a large Phase 3 biopsy-confirmed MASH trial. They do not establish superiority over resmetirom in a head-to-head sense; the populations differ, the fibrosis stage distributions differ, and the endpoints are operationalized differently. But they place semaglutide firmly in the leading tier of MASH therapeutics with high-quality evidence from a major peer-reviewed journal.

The Part 2 Question: Will Semaglutide Prevent Cirrhosis?

The most clinically consequential question in MASH pharmacotherapy is not whether a drug can improve biopsy readings at 72 weeks. It is whether treatment prevents the downstream clinical events that cause morbidity and mortality: cirrhosis, decompensated liver disease, hepatocellular carcinoma, liver transplantation, and liver-related death.

Histological improvement is a validated surrogate endpoint, supported by epidemiological data linking fibrosis stage to clinical outcomes (PMID: 26477328), but it is a surrogate. Regulatory agencies have granted accelerated approval based on histological endpoints while requiring confirmatory clinical outcome trials.

ESSENCE’s Part 2 is designed exactly as this confirmatory trial. The primary endpoint at week 240 is cirrhosis-free survival, a clinical outcome measure combining time to cirrhosis and all-cause mortality. With 1,205 enrolled participants followed for five years, Part 2 has the statistical power to detect clinically meaningful differences in cirrhosis incidence and survival.

The trial completion date of April 2029 means these results are approximately three years from the time of this article. If the histological signal in Part 1 translates to clinical outcome benefit in Part 2, ESSENCE will have provided the definitive evidence package needed for broad regulatory approval of semaglutide in MASH.

For tirzepatide, a dual GIP/GLP-1 receptor agonist with greater weight loss magnitude than semaglutide in head-to-head comparison (SURMOUNT-5, NCT05822830), MASH trials are earlier in development. The additional weight loss from dual GIP/GLP-1 agonism raises the hypothesis that tirzepatide might produce even greater histological benefit than semaglutide in MASH, but this remains to be tested in adequately powered trials with liver biopsy endpoints.

What the ESSENCE Data Mean for the MASH Field

PMID: 40305708 and NCT04822181 together mark a turning point. A GLP-1 receptor agonist with an established safety and efficacy record across multiple metabolic indications has now demonstrated Phase 3 liver histology improvement in MASH at a magnitude exceeding what most of the field anticipated from a weight-loss mechanism alone.

Several implications follow.

For hepatologists and gastroenterologists: The ESSENCE data, alongside resmetirom approval, shift the treatment conversation from “no effective pharmacotherapy” to “which pharmacotherapy and for which patients.” Semaglutide’s weight loss benefit, systemic cardiovascular risk reduction (demonstrated in SUSTAIN-6 and SELECT trials), and now liver histology benefit create a compelling multi-system case for GLP-1RA use in MASH patients with obesity or cardiovascular comorbidities.

For the regulatory pathway: If FDA reviews the ESSENCE Part 1 data in support of a supplemental NDA (sNDA) for the MASH indication, the histological endpoint effect sizes are large enough to comfortably meet the accelerated approval standard established by the resmetirom precedent. Part 2 clinical outcomes data would then serve as the confirmatory commitment.

For drug combination strategies: MASH is a multifactorial disease. Weight loss alone does not fully explain the 62.9% steatohepatitis resolution rate in ESSENCE; the placebo group lost 2% of body weight and still achieved 34.3% resolution, suggesting background lifestyle interventions and natural disease variability play a role. Future combination trials pairing semaglutide with complementary agents targeting fibrogenesis directly (such as FXR agonists, FGF21 analogs, or anti-fibrotic compounds) may push response rates higher.

For retatrutide: The triple GIP/GLP-1/glucagon receptor agonist in Phase 3 development produces greater weight loss than either semaglutide or tirzepatide in early trials, raising the hypothesis that greater obesity-driven MASH reversal is achievable. Whether the glucagon receptor component adds hepatic benefit, additive harm (glucagon can stimulate hepatic glucose production in some contexts), or is neutral, will require its own NASH/MASH histological trial data.

Caveats and What Remains Unknown

The data in this article derive from the published abstract and metadata for PMID: 40305708, available through PubMed. The complete NEJM publication contains the full statistical analysis plan, per-protocol versus intention-to-treat populations, subgroup analyses by fibrosis stage and diabetes status, complete adverse event tables, and the fidelity of biopsy reading (inter-reader variability in NASH histology is a known methodological challenge). Conclusions here reflect the abstract-level data only.

Several questions remain open:

• Do the histological improvements at week 72 durably prevent cirrhosis progression through week 240? Part 2 will answer this.
• Which patient subgroups (by fibrosis stage, diabetes status, BMI, age) derive the greatest histological benefit? Subgroup data in the full publication will clarify this.
• What is the durability of histological improvement after semaglutide discontinuation? This is not studied in ESSENCE, which is a continuous treatment trial.
• Do patients who achieve histological improvement at week 72 but then stop treatment before week 240 experience rebound? Long-term adherence and off-treatment durability data are not available.

This article is for research and informational purposes only. It does not constitute medical advice, treatment guidance, or an endorsement of any specific therapeutic approach. The data described are from a randomized controlled trial; their applicability to any individual patient depends on that patient’s full clinical context, assessed by a qualified clinician. No dosing guidance is implied or discussed.

Related Research on This Site

• Semaglutide Research Hub: GLP-1 receptor agonist mechanism, STEP trial evidence, cardiovascular outcome data, and pharmacokinetics
• Tirzepatide Research Hub: dual GIP/GLP-1 agonism, SURMOUNT trial data, head-to-head comparisons with semaglutide
• Retatrutide Research Hub: triple GIP/GLP-1/glucagon agonism, Phase 2 efficacy data, and Phase 3 pipeline status

Primary sources: Sanyal AJ et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med. 2025 Jun 5. PMID: 40305708. DOI: 10.1056/NEJMoa2413258. Trial registration: NCT04822181 (ClinicalTrials.gov, verified April 2026, active not recruiting). This article is for research and informational purposes only.